Ranibizumab-Eqrn: uses, dosing, side effects & brands
Ranibizumab-Eqrn is a medicine sold in the U.S. under one brand, for diabetic retinopathy, macular edema and retinal vein occlusion. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Diabetic Retinopathy, Macular Edema and Retinal Vein Occlusion
- Available as
- Injectable
- Sold as
- Cimerli
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How ranibizumab-eqrn is dosed
From the FDA label for Cimerli (application BLA761165). Other ranibizumab-eqrn products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
For ophthalmic intravitreal injection only ( 2.1 ) • Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 2.2 ): CIMERLI 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days). • Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment. • Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses. Patients should be assessed regularly. • Macular Edema Following Retinal Vein Occlusion (RVO) ( 2.3 ): CIMERLI 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days). • Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) ( 2.4 ): CIMERLI 0.3 mg (0.05 mL of 6 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days). • Myopic Choroidal Neovascularization (mCNV) ( 2.5 ): CIMERLI 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be initially administered by intravitreal injection once a month (approximately 28 days) for up to three months. Patients may be retreated if needed. 2.1 General Dosing Information FOR OPHTHALMIC INTRAVITREAL INJECTION. Vials : A 5-micron sterile filter needle (19-gauge × 1-1/2 inch), a 1-mL Luer lock syringe and a…
Ranibizumab-Eqrn side effects
The following adverse reactions are discussed in greater detail in other sections of the label: • Endophthalmitis and Retinal Detachments [see Warnings and Precautions ( 5.1 )] • Increases in Intraocular Pressure [see Warnings and Precautions ( 5.2 )] • Thromboembolic Events [see Warnings and Precautions ( 5.3 )] • Fatal Events in patients with DME and DR at baseline [see Warnings and Precautions ( 5.4 )] The most common adverse reactions (reported more frequently in ranibizumab-treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP ( 6.2 ). To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Injection Procedure Serious adverse reactions related to the injection procedure have occurred in < 0.1% of intravitreal injections, including endophthalmitis [see Warnings and Precautions ( 5.1 )] , rhegmatogenous retinal detachment, and iatrogenic traumatic cataract. 6.2 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data below reflect exposure to 0.5 mg ranibizumab in 440 patients with neovascular AMD in…
Who shouldn’t take ranibizumab-eqrn
Ocular or periocular infections ( 4.1 ) • Hypersensitivity ( 4.2 ) 4.1 Ocular or Periocular Infections CIMERLI is contraindicated in patients with ocular or periocular infections. 4.2 Hypersensitivity CIMERLI is contraindicated in patients with known hypersensitivity to ranibizumab products or any of the excipients in CIMERLI. Hypersensitivity reactions may manifest as severe intraocular inflammation.
Ranibizumab-Eqrn drug interactions
Drug interaction studies have not been conducted with ranibizumab products. Ranibizumab intravitreal injection has been used adjunctively with PDT. Twelve of 105 (11%) patients with neovascular AMD developed serious intraocular inflammation; in 10 of the 12 patients, this occurred when ranibizumab was administered 7 days (± 2 days) after PDT.
Every ranibizumab-eqrn product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Cimerli.
Related calculators
Frequently asked questions
What is ranibizumab-eqrn?
Cimerli (Ranibizumab-Eqrn) is a medication used to treat Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion.
Can you take ranibizumab-eqrn with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run ranibizumab-eqrn against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does ranibizumab-eqrn come in?
Across the brands we track, ranibizumab-eqrn is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic ranibizumab-eqrn?
We do not currently list a generic-labelled ranibizumab-eqrn product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Ranibizumab-Eqrn: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/ranibizumab-eqrn
- MLA
- “Ranibizumab-Eqrn: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/ranibizumab-eqrn.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for ranibizumab-eqrn on DailyMed (NIH) ↗.